Yousef Zakharia, MD

Articles by Yousef Zakharia, MD

Dr Zakharia on Long-Term Benefit With Nivolumab Plus Ipilimumab in ccRCC

January 28th 2025

Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma.

Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC

ByYousef Zakharia, MD

November 11th 2023

Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.

Dr. Zakharia on the Role of Seleno-L-Methionine in Previously Treated Advanced RCC

ByYousef Zakharia, MD

October 11th 2021

Yousef Zakharia, MD, discusses the role of seleno-L-methionine in previously treated advanced clear cell renal cell carcinoma.

Yousef Zakharia, MD

Articles by Yousef Zakharia, MD

Dr Zakharia on Long-Term Benefit With Nivolumab Plus Ipilimumab in ccRCC

Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC

Dr. Zakharia on the Role of Seleno-L-Methionine in Previously Treated Advanced RCC

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies